URMC Research Network

Find People
Keyword
Last Name
 
More Search Options

Jacob Schlesinger

TitleProfessor Emeritus
InstitutionSchool of Medicine and Dentistry
DepartmentMedicine
Address11 Cavan Way
Pittsford NY 14534
 
 Selected Publications
  • Thibodeaux BA, Garbino NC, Liss NM, Piper J, Schlesinger JJ, Blair CD, Roehrig JT. A humanized IgG but not IgM antibody is effective in prophylaxis and therapy of yellow fever infection in an AG129/17D-204 peripheral challenge mouse model. Antiviral Res. 2012 Apr; 94(1):1-8.
    View in: PubMed
  • Kou Z, Lim JY, Beltramello M, Quinn M, Chen H, Liu S, Liu SN, Martinez-Sobrido L, Martnez-Sobrido L, Diamond MS, Schlesinger JJ, de Silva A, Sallusto F, Jin X. Human antibodies against dengue enhance dengue viral infectivity without suppressing type I interferon secretion in primary human monocytes. Virology. 2011 Feb 5; 410(1):240-7.
    View in: PubMed
  • Block OK, Rodrigo WW, Quinn M, Jin X, Rose RC, Schlesinger JJ. A tetravalent recombinant dengue domain III protein vaccine stimulates neutralizing and enhancing antibodies in mice. Vaccine. 2010 Nov 29; 28(51):8085-94.
    View in: PubMed
  • Rodrigo WW, Block OK, Lane C, Sukupolvi-Petty S, Goncalvez AP, Johnson S, Diamond MS, Lai CJ, Rose RC, Jin X, Schlesinger JJ. Dengue virus neutralization is modulated by IgG antibody subclass and Fcgamma receptor subtype. Virology. 2009 Nov 25; 394(2):175-82.
    View in: PubMed
  • Arévalo MT, Simpson-Haidaris PJ, Kou Z, Schlesinger JJ, Jin X. Primary human endothelial cells support direct but not antibody-dependent enhancement of dengue viral infection. J Med Virol. 2009 Mar; 81(3):519-28.
    View in: PubMed
  • Shanaka WW, Rodrigo I, Alcena DC, Rose RC, Jin X, Schlesinger JJ. An automated Dengue virus microneutralization plaque assay performed in human Fc{gamma} receptor-expressing CV-1 cells. Am J Trop Med Hyg. 2009 Jan; 80(1):61-5.
    View in: PubMed
  • Jin X, Block OT, Rose R, Schlesinger J. Dengue vaccine development and dengue viral neutralization and enhancement assays. Antivir Ther. 2009; 14(6):739-49.
    View in: PubMed
  • Rodrigo WW, Alcena DC, Kou Z, Kochel TJ, Porter KR, Comach G, Rose RC, Jin X, Schlesinger JJ. Difference between the abilities of human Fcgamma receptor-expressing CV-1 cells to neutralize American and Asian genotypes of dengue virus 2. Clin Vaccine Immunol. 2009 Feb; 16(2):285-7.
    View in: PubMed
  • Sapinoro R, Volcy K, Rodrigo WW, Schlesinger JJ, Dewhurst S. Fc receptor-mediated, antibody-dependent enhancement of bacteriophage lambda-mediated gene transfer in mammalian cells. Virology. 2008 Apr 10; 373(2):274-86.
    View in: PubMed
  • Kou Z, Quinn M, Chen H, Rodrigo WW, Rose RC, Schlesinger JJ, Jin X. Monocytes, but not T or B cells, are the principal target cells for dengue virus (DV) infection among human peripheral blood mononuclear cells. J Med Virol. 2008 Jan; 80(1):134-46.
    View in: PubMed
  • Blackley S, Kou Z, Chen H, Quinn M, Rose RC, Schlesinger JJ, Coppage M, Jin X. Primary human splenic macrophages, but not T or B cells, are the principal target cells for dengue virus infection in vitro. J Virol. 2007 Dec; 81(24):13325-34.
    View in: PubMed
  • Sukupolvi-Petty S, Austin SK, Purtha WE, Oliphant T, Nybakken GE, Schlesinger JJ, Roehrig JT, Gromowski GD, Barrett AD, Fremont DH, Diamond MS. Type- and subcomplex-specific neutralizing antibodies against domain III of dengue virus type 2 envelope protein recognize adjacent epitopes. J Virol. 2007 Dec; 81(23):12816-26.
    View in: PubMed
  • Schlesinger JJ. Flavivirus nonstructural protein NS1: complementary surprises. Proc Natl Acad Sci U S A. 2006 Dec 12; 103(50):18879-80.
    View in: PubMed
  • Rodrigo WW, Jin X, Blackley SD, Rose RC, Schlesinger JJ. Differential enhancement of dengue virus immune complex infectivity mediated by signaling-competent and signaling-incompetent human Fcgamma RIA (CD64) or FcgammaRIIA (CD32). J Virol. 2006 Oct; 80(20):10128-38.
    View in: PubMed
  • Schlesinger J, Arama D, Noy H, Dagash M, Belinky P, Gross G. In-cell generation of antibody single-chain Fv transcripts by targeted RNA trans-splicing. J Immunol Methods. 2003 Nov; 282(1-2):175-86.
    View in: PubMed
  • Chambers TJ, Liang Y, Droll DA, Schlesinger JJ, Davidson AD, Wright PJ, Jiang X. Yellow fever virus/dengue-2 virus and yellow fever virus/dengue-4 virus chimeras: biological characterization, immunogenicity, and protection against dengue encephalitis in the mouse model. J Virol. 2003 Mar; 77(6):3655-68.
    View in: PubMed
  • Schlesinger JJ, Chapman SE. Influence of the human high-affinity IgG receptor FcgammaRI (CD64) on residual infectivity of neutralized dengue virus. Virology. 1999 Jul 20; 260(1):84-8.
    View in: PubMed
  • Ryman KD, Ledger TN, Weir RC, Schlesinger JJ, Barrett AD. Yellow fever virus envelope protein has two discrete type-specific neutralizing epitopes. J Gen Virol. 1997 Jun; 78 ( Pt 6):1353-6.
    View in: PubMed
  • Kaufman BA, Moran CJ, Schlesinger J. Fluoroscopy of programmable cerebrospinal fluid shunt valve settings. Technical illustration. J Neurosurg. 1997 Apr; 86(4):735.
    View in: PubMed
  • Schlesinger JJ, Chapman S, Nestorowicz A, Rice CM, Ginocchio TE, Chambers TJ. Replication of yellow fever virus in the mouse central nervous system: comparison of neuroadapted and non-neuroadapted virus and partial sequence analysis of the neuroadapted strain. J Gen Virol. 1996 Jun; 77 ( Pt 6):1277-85.
    View in: PubMed
  • Schlesinger JJ, Chapman S. Neutralizing F(ab')2 fragments of protective monoclonal antibodies to yellow fever virus (YF) envelope protein fail to protect mice against lethal YF encephalitis. J Gen Virol. 1995 Jan; 76 ( Pt 1):217-20.
    View in: PubMed
  • Eckels KH, Dubois DR, Summers PL, Schlesinger JJ, Shelly M, Cohen S, Zhang YM, Lai CJ, Kurane I, Rothman A, et al. Immunization of monkeys with baculovirus-dengue type-4 recombinants containing envelope and nonstructural proteins: evidence of priming and partial protection. Am J Trop Med Hyg. 1994 Apr; 50(4):472-8.
    View in: PubMed
  • Schlesinger JJ, Foltzer M, Chapman S. The Fc portion of antibody to yellow fever virus NS1 is a determinant of protection against YF encephalitis in mice. Virology. 1993 Jan; 192(1):132-41.
    View in: PubMed
  • Megret F, Hugnot JP, Falconar A, Gentry MK, Morens DM, Murray JM, Schlesinger JJ, Wright PJ, Young P, Van Regenmortel MH, et al. Use of recombinant fusion proteins and monoclonal antibodies to define linear and discontinuous antigenic sites on the dengue virus envelope glycoprotein. Virology. 1992 Apr; 187(2):480-91.
    View in: PubMed
  • Leu S, Schlesinger J, Michaels A, Shavit N. Complete DNA sequence of the Chlamydomonas reinhardtii chloroplast atpA gene. Plant Mol Biol. 1992 Feb; 18(3):613-6.
    View in: PubMed
  • Schlesinger JJ, Putnak JR, Eckels KH. New approaches to flavivirus vaccine development. Biotechnology. 1992; 20:289-307.
    View in: PubMed
  • Deubel V, Bordier M, Megret F, Gentry MK, Schlesinger JJ, Girard M. Processing, secretion, and immunoreactivity of carboxy terminally truncated dengue-2 virus envelope proteins expressed in insect cells by recombinant baculoviruses. Virology. 1991 Jan; 180(1):442-7.
    View in: PubMed
  • Barrett AD, Monath TP, Cropp CB, Adkins JA, Ledger TN, Gould EA, Schlesinger JJ, Kinney RM, Trent DW. Attenuation of wild-type yellow fever virus by passage in HeLa cells. J Gen Virol. 1990 Oct; 71 ( Pt 10):2301-6.
    View in: PubMed
  • Falgout B, Bray M, Schlesinger JJ, Lai CJ. Immunization of mice with recombinant vaccinia virus expressing authentic dengue virus nonstructural protein NS1 protects against lethal dengue virus encephalitis. J Virol. 1990 Sep; 64(9):4356-63.
    View in: PubMed
  • Putnak JR, Schlesinger JJ. Protection of mice against yellow fever virus encephalitis by immunization with a vaccinia virus recombinant encoding the yellow fever virus non-structural proteins, NS1, NS2a and NS2b. J Gen Virol. 1990 Aug; 71 ( Pt 8):1697-702.
    View in: PubMed
  • Brandriss MW, Schlesinger JJ, Walsh EE. Immunogenicity of a purified fragment of 17D yellow fever envelope protein. J Infect Dis. 1990 Jun; 161(6):1134-9.
    View in: PubMed
  • Schlesinger JJ, Brandriss MW, Putnak JR, Walsh EE. Cell surface expression of yellow fever virus non-structural glycoprotein NS1: consequences of interaction with antibody. J Gen Virol. 1990 Mar; 71 ( Pt 3):593-9.
    View in: PubMed
  • Walsh EE, Hall CB, Schlesinger JJ, Brandriss MW, Hildreth S, Paradiso P. Comparison of antigenic sites of subtype-specific respiratory syncytial virus attachment proteins. J Gen Virol. 1989 Nov; 70 ( Pt 11):2953-61.
    View in: PubMed
  • Henchal EA, Henchal LS, Schlesinger JJ. Synergistic interactions of anti-NS1 monoclonal antibodies protect passively immunized mice from lethal challenge with dengue 2 virus. J Gen Virol. 1988 Aug; 69 ( Pt 8):2101-7.
    View in: PubMed
  • Gibson CA, Schlesinger JJ, Barrett AD. Prospects for a virus non-structural protein as a subunit vaccine. Vaccine. 1988 Feb; 6(1):7-9.
    View in: PubMed
  • Lobigs M, Dalgarno L, Schlesinger JJ, Weir RC. Location of a neutralization determinant in the E protein of yellow fever virus (17D vaccine strain). Virology. 1987 Dec; 161(2):474-8.
    View in: PubMed
  • Walsh EE, Brandriss MW, Schlesinger JJ. Immunological differences between the envelope glycoproteins of two strains of human respiratory syncytial virus. J Gen Virol. 1987 Aug; 68 ( Pt 8):2169-76.
    View in: PubMed
  • Walsh EE, Hall CB, Briselli M, Brandriss MW, Schlesinger JJ. Immunization with glycoprotein subunits of respiratory syncytial virus to protect cotton rats against viral infection. J Infect Dis. 1987 Jun; 155(6):1198-204.
    View in: PubMed
  • Schlesinger JJ, Brandriss MW, Walsh EE. Protection of mice against dengue 2 virus encephalitis by immunization with the dengue 2 virus non-structural glycoprotein NS1. J Gen Virol. 1987 Mar; 68 ( Pt 3):853-7.
    View in: PubMed
  • Deubel V, Schlesinger JJ, Digoutte JP, Girard M. Comparative immunochemical and biological analysis of African and South American yellow fever viruses. Arch Virol. 1987; 94(3-4):331-8.
    View in: PubMed
  • Schlesinger JJ, Brandriss MW, Cropp CB, Monath TP. Protection against yellow fever in monkeys by immunization with yellow fever virus nonstructural protein NS1. J Virol. 1986 Dec; 60(3):1153-5.
    View in: PubMed
  • Rice CM, Aebersold R, Teplow DB, Pata J, Bell JR, Vorndam AV, Trent DW, Brandriss MW, Schlesinger JJ, Strauss JH. Partial N-terminal amino acid sequences of three nonstructural proteins of two flaviviruses. Virology. 1986 May; 151(1):1-9.
    View in: PubMed
  • Walsh EE, Cote PJ, Fernie BF, Schlesinger JJ, Brandriss MW. Analysis of the respiratory syncytial virus fusion protein using monoclonal and polyclonal antibodies. J Gen Virol. 1986 Mar; 67 ( Pt 3):505-13.
    View in: PubMed
  • Brandriss MW, Schlesinger JJ, Walsh EE, Briselli M. Lethal 17D yellow fever encephalitis in mice. I. Passive protection by monoclonal antibodies to the envelope proteins of 17D yellow fever and dengue 2 viruses. J Gen Virol. 1986 Feb; 67 ( Pt 2):229-34.
    View in: PubMed
  • Monath TP, Hill LJ, Brown NV, Cropp CB, Schlesinger JJ, Saluzzo JF, Wands JR. Sensitive and specific monoclonal immunoassay for detecting yellow fever virus in laboratory and clinical specimens. J Clin Microbiol. 1986 Jan; 23(1):129-34.
    View in: PubMed
  • Schlesinger JJ, Brandriss MW, Walsh EE. Protection against 17D yellow fever encephalitis in mice by passive transfer of monoclonal antibodies to the nonstructural glycoprotein gp48 and by active immunization with gp48. J Immunol. 1985 Oct; 135(4):2805-9.
    View in: PubMed
  • Deubel V, Pailliez JP, Cornet M, Schlesinger JJ, Diop M, Diop A, Digoutte JP, Girard M. Homogeneity among Senegalese strains of yellow fever virus. Am J Trop Med Hyg. 1985 Sep; 34(5):976-83.
    View in: PubMed
  • Walsh EE, Brandriss MW, Schlesinger JJ. Purification and characterization of the respiratory syncytial virus fusion protein. J Gen Virol. 1985 Mar; 66 ( Pt 3):409-15.
    View in: PubMed
  • Schlesinger JJ, Walsh EE, Brandriss MW. Analysis of 17D yellow fever virus envelope protein epitopes using monoclonal antibodies. J Gen Virol. 1984 Oct; 65 ( Pt 10):1637-44.
    View in: PubMed
  • Monath TP, Schlesinger JJ, Brandriss MW, Cropp CB, Prange WC. Yellow fever monoclonal antibodies: type-specific and cross-reactive determinants identified by immunofluorescence. Am J Trop Med Hyg. 1984 Jul; 33(4):695-8.
    View in: PubMed
  • Walsh EE, Schlesinger JJ, Brandriss MW. Purification and characterization of GP90, one of the envelope glycoproteins of respiratory syncytial virus. J Gen Virol. 1984 Apr; 65 ( Pt 4):761-7.
    View in: PubMed
  • Brandriss MW, Schlesinger JJ. Antibody-mediated infection of P388D1 cells with 17D yellow fever virus: effects of chloroquine and cytochalasin B. J Gen Virol. 1984 Apr; 65 ( Pt 4):791-4.
    View in: PubMed
  • Walsh EE, Schlesinger JJ, Brandriss MW. Protection from respiratory syncytial virus infection in cotton rats by passive transfer of monoclonal antibodies. Infect Immun. 1984 Feb; 43(2):756-8.
    View in: PubMed
  • Burstin SJ, Brandriss MW, Schlesinger JJ. Infection of a macrophage-like cell line, P388D1 with reovirus; effects of immune ascitic fluids and monoclonal antibodies on neutralization and on enhancement of viral growth. J Immunol. 1983 Jun; 130(6):2915-9.
    View in: PubMed
  • Schlesinger JJ, Brandriss MW. 17D yellow fever virus infection of P388D1 cells mediated by monoclonal antibodies: properties of the macrophage Fc receptor. J Gen Virol. 1983 Jun; 64 (Pt 6):1255-62.
    View in: PubMed
  • Monath TP, Kinney RM, Schlesinger JJ, Brandriss MW, Brès P. Ontogeny of yellow fever 17D vaccine: RNA oligonucleotide fingerprint and monoclonal antibody analyses of vaccines produced world-wide. J Gen Virol. 1983 Mar; 64 Pt 3:627-37.
    View in: PubMed
  • Schlesinger JJ, Brandriss MW, Monath TP. Monoclonal antibodies distinguish between wild and vaccine strains of yellow fever virus by neutralization, hemagglutination inhibition, and immune precipitation of the virus envelope protein. Virology. 1983 Feb; 125(1):8-17.
    View in: PubMed
  • Brandriss MW, Schlesinger JJ, Chapman SE. Growth of measles virus in a human macrophagelike cell line: U937. Am J Pathol. 1982 Nov; 109(2):179-83.
    View in: PubMed
  • Brandriss MW, Schlesinger JJ, Douglas RG. Responses of elderly subjects to a new subunit influenza virus vaccine. J Infect Dis. 1982 Feb; 145(2):277.
    View in: PubMed
  • Schlesinger JJ, Brandriss MW. Growth of 17D yellow fever virus in a macrophage-like cell line, U937: role of Fc and viral receptors in antibody-mediated infection. J Immunol. 1981 Aug; 127(2):659-65.
    View in: PubMed
  • Schlesinger JJ, Brandriss MW. Antibody-mediated infection of macrophages and macrophage-like cell lines with 17D-yellow fever virus. J Med Virol. 1981; 8(2):103-17.
    View in: PubMed
  • Schlesinger JJ, Dubois JG, Beaver PC. Brugia-like filarial infection acquired in the United States. Am J Trop Med Hyg. 1977 Mar; 26(2):204-7.
    View in: PubMed

Visualizations


Schlesinger's Networks

Concepts
See all (229) concept(s)
_
Co-Authors
See all (8) people
_
Similar People
See all (60) people
_
Same Department
Search Department